Phase IB study of osimertinib in combination with navitoclax in EGFR-mutant NSCLC following resistance to initial EGFR therapy (ETCTN 9903)

INTRODUCTION: Osimertinib is an effective therapy in EGFR mutant NSCLC, but resistance invariably develops. Navitoclax is an oral inhibitor of BCL-2/BCL-xL that has exhibited synergy with osimertinib in preclinical models of EGFR-mutant NSCLC. In hematologic malignancies, BCL-2 family inhibitors in...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Clin Cancer Res
Autori principali: Bertino, Erin M., Gentzler, Ryan D., Clifford, Sarah, Kolesar, Jill, Muzikansky, Alona, Haura, Eric B., Piotrowska, Zofia, Camidge, D. Ross, Stinchcombe, Thomas E., Hann, Christine, Malhotra, Jyoti, Villaruz, Liza C., Paweletz, Cloud P., Lau, Christie L., Sholl, Lynette, Takebe, Naoko, Moscow, Jeffrey A., Shapiro, Geoffrey I., Jänne, Pasi A., Oxnard, Geoffrey R.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2020
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7976451/
https://ncbi.nlm.nih.gov/pubmed/33376097
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-20-4084
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi